INO Inovio Pharmaceuticals, Inc.
Healthcare$1.26-6.67%ClosedMarket Cap: $67.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
153.74
P/S
0.00
EV/EBITDA
-0.65
DCF Value
$0.07
FCF Yield
-115.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-666.5%
ROA
-170.6%
ROIC
-567.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-21.9M | $-19.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-17.5M | $3.8M | $— | — |
| FY null | $65.3K | 100.0% | $-86.8M | $-84.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-21.2M | $-45.5M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-23.1M | $-23.5M | $— | — |
| Q1 null | $65.3K | 100.0% | $-25.1M | $-19.7M | $— | — |
| Q4 null | $117.0K | -563.1% | $-20.4M | $-19.4M | $— | — |
| FY null | $217.8K | 100.0% | $-112.4M | $-107.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-27.3M | $-25.2M | $— | — |
| Q2 null | $100.8K | -722.4% | $-33.2M | $-32.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-31.5M | $-30.5M | $— | — |
| Q4 2023 | $102.7K | -70.7% | $-27.4M | $-25.0M | $-1.10 | — |